



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>2</u> of <u>5</u>		C mplet if Known	
		Application Number	10/664,803
		Filing Date	September 19, 2003
		First Named Inventor	Unchalee Kositprapa
		Art Unit	
		Examiner Name	
		Attorney Docket Number	141-424

U.S. PATENT DOCUMENTS					
Examiner Initials ²	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ³ (if known)			
	AU	US- 5,955,106	09-21-1999	Moeckel et al.	
	AV	US-6,011,049	01-04-2000	Whitcomb	
	AW	US-6,031,004	02-29-2000	Timmins et al.	
	AX	US-6,099,859	08-08-2000	Cheng et al.	
	AY	US-6,153,632	11-28-2000	Rieveley	
	AZ	US- 6,191,162	02-20-2001	Byrd et al.	
	BA	US- 6,248,363	06-19-2001	Patel et al.	
	BB	US- 6,291,495	09-18-2001	Rieveley	
	BC	US- 6,296,874	10-02-2001	Cutie et al.	
	BD	US- 6,329,403	12-11-2001	Odaka et al.	
	BE	US- 6,383,471	05-07-2002	Chen et al.	
	BF	US-6,403,121	06-11-2002	Adjei et al.	
	BG	US- 2002/0071866	06-13-2002	Geerke	
	BH	US- 6,451,342	09-17-2002	Adjei et al.	
	BI	US-6,475,521	11-05-2002	Timmins et al.	
	BJ	US- 6,524,621	02-25-2003	Adjei et al.	
	BK	US- 2003/0113371	06-19-2003	Dhawan et al.	
	BL	US- 2003/0118647	06-26-2003	Seth	
	BM	US- 2003/0118649	06-26-2003	Gao et al.	
	BN	US- 6,599,284	07-29-2003	Faour	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ²	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	CA	WO 96/09823 ✓	04-04-1996	Luo et al.		
	CB	WO 98/11879 ✓	03-26-1998	Shell et al.		
	CC	WO 98/55107 ✓	12-10-1998	Shell et al.		
	CD	WO 99/47128 ✓	09-23-1999	Timmins et al.		
	CE	WO 99/55320 ✓	11-04-1999	Nishii et al.		
	CF	WO 00/28989 ✓	05-25-2000	Lewis et al.		
	CG	WO 00/72827 ✓	12-07-2000	Straub et al.		
	CH	WO 01/35940	05-25-2001	Lewis et al.		
	CI	WO 01/35941	05-25-2001	Lilliot et al.		
	CJ	WO 01/82875	11-08-2001	Cutie et al.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/664,803
		Filing Date	September 19, 2003
		First Named Inventor	Unchalee Kositprapa
		Group Art Unit	
		Examiner Name	
Sheet 4 of 5	Attorney Docket Number	141-424	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	DA	P. Karttunen et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, "The pharmacokinetics of metformin: a comparison of the properties of a rapid release and a sustained-release preparation" Vol. 21, No. 1 - 1983, pp. 31-36.	
	DB	P.J. Pentikainen, International Journal of Clinical Pharmacology, Therapy and Toxicology, "Bioavailability of metformin. Comparison of solution, rapidly dissolving-tablet, and three sustained-release products", Vol. 24, No. 4 - 1986, pp. 213-220.	
	DC	Finnish Monograph of the Diformin®, Retard tablet, with English translation 2001	
	DD	O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update "The status of metformin in Canada" Vol. 128, January 1, 1983, pgs. 24-26.	
	DE	G. Belcher and D.R. Matthews Experiment and Clinical Endocrinology & Diabetes, "Safety and tolerability of pioglitazone" Suppl. 2 (2000) pgs. 267-273.	
	DF	Daniel Einhorn, MD et al., Clinical Therapeutics "Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study", Vol. 22, No. 12, 2000 pgs. 1395-1413.	
	DG	National Institute for Clinical Excellence Technology Appraisal Guidance - No. 21, "Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus" March 2001, pgs. 1-13.	
	DH	The Pharmaceutical Journal, Vol. 265, No. 7122, p. 710 November 11, 2000 Clinical (abstract only).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Completion if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/664,803
		Filing Date	September 19, 2003
		First Named Inventor	Unchalee Kositprapa
		Group Art Unit	
		Examiner Name	
Sheet 5 of 5		Attorney Docket Number	141-424

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	DI	Product Labeling for Glucophage® XR (July 2002).	
	DJ	ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117 June 1999.	
	DK	Website www.findarticles.com, Clinician Reviews, "Insulin-Sensitizing Diabetes Agent" September 1999.	
	DL	ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175	
	DM	Rote Liste No. 11081 the Medicament Mediabet of MEDICE, Chem.-Pharm. Fabrik Pütter GmbH & Co. KG, Kuhlweg 37-39 Iserlohn/Germany, Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993.	

Examiner Signature	/Aradhana Sasan/	Date Considered	06/21/2010
-------------------------------	------------------	----------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./